Advertisement

Topics

Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

12:06 EDT 14 Jun 2018 | OncLive

The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.

Original Article: Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

NEXT ARTICLE

More From BioPortfolio on "Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space"

Advertisement
Quick Search
Advertisement
Advertisement